Almirall, S.A.: Almirall: Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

- Skin clearance and itch, key signs and symptoms of atopic dermatitis, were significantly improved with lebrikizumab treatment in combination with TCS BARCELONA, Spain, April 11, 2022

Related Keywords

Germany ,New York ,United States ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Spanish ,Andreas Pinter ,Eli Lilly ,Karl Ziegelbauer ,Clinical Research ,Drug Administration ,University Hospital In Frankfurt Main Germany ,Spanish Stock Exchange ,Annual Revolutionizing Atopic Dermatitis ,University Hospital ,Lotus Mallbris ,Eczema Area ,Severity Index ,Investigator Global Assessment ,Pruritus Numeric Rating Scale ,Dermatology Life Quality ,Fast Track ,Noble Purpose ,Inflammatory Skin Disease Summit ,Cutaneous Medicine ,Almirall ,Lebrikizumab ,Combined ,Ropical ,Corticosteroids ,Howed ,Significant ,Improvements ,Disease ,Severity ,Topic ,Dermatitis ,